#EULAR2021 LB0004: Secukinumab for enthesitis-related JIA treatment-withdrawal study shows longer time to flare and decreased flares compared to PBO @Rheumnow
EULAR 2021 Tweet by Eric Dein
Tweet
Related Content
Dr. Jack Cush reviews the news and journal reports from this past week on RheumNow.com.17 Sept EMA CHMP recommended marketing authorisation for secukinumab (Cosentyx) in the treatment of polymyalgia rheumatica. BUT- not yet EMA approved in the EU. https://t.co/ZGUSbw06vXNew report shows Median…
Dr. Antoni Chan reports on abstract OP0186 in London at EULAR 2026
Dr. Jack Cush reviews the news and journal articles from the past week on RheumNow.com.Upadacitinib is now approved in European Union to treat active polyarticular juvenile idiopathic arthritis (pJIA) ages > 2yrs for those not responding to 1+ DMARDs. In the USA, UPA is approved for pJIA &…
